具有肾脏意义的单克隆免疫球蛋白病的发病机制研究

1. Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood, 2012, 120(22): 4292-4295. 2. Sethi S, Fervenza FC, Rajkumar SV. Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. Curr Opin Nephrol Hypertens, 2016, 25(2): 127-137. 3. Bridoux F, Leung N, Hutchison CA, et al. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int, 2015, 87(4): 698-711. 4. Ramirez-Alvarado M, Barnidge DR, Murray DL, et al. Assessment of renal response with urinary exosomes in patients with AL amyloidosis: a proof of concept. Am J Hematol, 2017, 92(6): 536-541. 5. Herrera GA, Teng J, Turbat-Herrera EA, et al. Understanding mesangial pathobiology in AL-amyloidosis and monoclonal Ig light chain deposition disease. Kidney Int Rep, 2020, 5(11): 1870-1893. 6. Teng J, Turbat-Herrera EA, Herrera GA. Extrusion of amyloid fibrils to the extracellular space in experimental mesangial AL-amyloidosis: transmission and scanning electron microscopy studies and correlation with renal biopsy observations. Ultrastruct Pathol, 2014, 38(2): 104-115. 7. Sirac C, Bridoux F. Mesangial cells as amyloid factory: a unique contribution of animal models. Kidney Int, 2014, 86(4): 669-671. 8. Teng J, Turbat-Herrera EA, Herrera GA. An animal model of glomerular light-chain-associated amyloidogenesis depicts the crucial role of lysosomes. Kidney Int, 2014, 86(4): 738-746. 9. Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med, 2020, 289(3): 268-292. 10. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet, 2016, 387(10038): 2641-2654. 11. Vora M, Kevil CG, Herrera GA. Contribution of human smooth muscle cells to amyloid angiopathy in AL (light-chain) amyloidosis. Ultrastruct Pathol, 2017, 41(5): 358-368. 12. Leo A, Kreft H, Hack H, et al. Restriction in the repertoire of the immunoglobulin light chain subgroup in pathological cold agglutinins with anti-prspecificity. Vox Sang, 2014, 86(2): 141-147. 13. James LC, Jones PC, McCoy A, et al. Beta-edge interactions in a pentadecameric human antibody V kappa domain. J Mol Biol, 2007, 367(3): 603-608. 14. Taylor EB, Ryan MJ. Freedom isn’t always free: immunoglobulin free light chains promote renal fibrosis. J Clin Invest, 2019, 129(7): 2660-2662. 15. Herrera GA, Del Pozo-Yauner L, Teng J, et al. Glomerulopathic light chain-mesangial cell interactions: sortilin-related receptor (SORL1) and signaling. Kidney Int Rep, 2021, 6(5): 1379-1396. 16. Vidal R, Goñi F, Stevens F, et al. Somatic mutations of the L12a gene in V-kappa (1) light chain deposition disease: potential effects on aberrant protein conformation and deposition. Am J Pathol, 1999, 155(6): 2009-2017. 17. Keeling J, Herrera GA. Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage. Kidney Int, 2015, 68(4): 1590-1603. 18. Herrera GA, Turbat-Herrera EA, Teng J. Animal models of light chain deposition disease provide a better understanding of nodular glomerulosclerosis. Nephron, 2016, 132(2): 119-136. 19. Ahmad SB, Bomback AS. C3 glomerulopathy: pathogenesis and treatment. Adv Chronic Kidney Dis, 2020, 27(2): 104-110. 20. Imamura H, Konomoto T, Tanaka E, et al. Familial C3 glomerulonephritis associated with mutations in the gene for complement factor B. Nephrol Dial Transplant, 2015, 30(5): 862-864. 21. Zipfel PF, Wiech T, Stea ED, et al. CFHR gene variations provide insights in the pathogenesis of the kidney diseases atypical hemolytic uremic syndrome and C3 glomerulopathy. J Am Soc Nephrol, 2020, 31(2): 241-256. 22. Iatropoulos P, Noris M, Mele C, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol, 2016, 71: 131-142. 23. Bhutani G, Nasr SH, Said SM, et al. Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc, 2015, 90(5): 587-596. 24. Kousios A, Duncan N, Tam FWK, et al. Proliferative glomerulonephritis with monoclonal Ig deposits (PGNMID): diagnostic and treatment challenges for the nephrologist!. Kidney Int, 2019, 95(2): 467-468. 25. Fogo AB, Lusco MA, Najafian B, et al. AJKD atlas of renal pathology: immunotactoid glomerulopathy. Am J Kidney Dis, 2015, 66(4): e29-e30. 26. Nasr SH, Kudose SS, Said SM, et al. Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants. Kidney Int, 2021, 99(2): 410-420. 27. Herrera GA. Proximal tubulopathies associated with monoclonal light chains: the spectrum of clinicopathologic manifestations and molecular pathogenesis. Arch Pathol Lab Med, 2014, 138(10): 1365-1380. 28. Yu XJ, Zhou XJ, Wang SX, et al. Monoclonal light chain crystalline podocytopathy and tubulopathy associated with monoclonal gammopathy of renal significance: a case report and literature review. BMC Nephrol, 2018, 19(1): 322. 29. Ecotière L, Thierry A, Debiais-Delpech C, et al. Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients. Nephrol Dial Transplant, 2016, 31(1): 64-72. 30. Stokes MB, Valeri AM, Herlitz L, et al. Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment Era. J Am Soc Nephrol, 2016, 27(5): 1555-1565. 31. Sengul S, Erturk S, Khan AM, et al. Receptor-associated protein blocks internalization and cytotoxicity of myeloma light chain in cultured human proximal tubular cells. PLoS One, 2013, 8(7): e70276. 32. Lusco MA, Fogo AB, Najafian B, et al. AJKD atlas of renal pathology: light chain cast nephropathy. Am J Kidney Dis, 2016, 67(3): e17-e18. 33. Weiss JH, Williams RH, Galla JH, et al. Pathophysiology of acute Bence-Jones protein nephrotoxicity in the rat. Kidney Int, 1981, 20(2): 198-210. 34. Walther C, Podoll AS, Finkel KW. Treatment of acute kidney injury with cast nephropathy. Clin Nephrol, 2014, 82(1): 1-6. 35. Manohar S, Nasr SH, Leung N. Light chain cast nephropathy: practical considerations in the management of myeloma kidney-what we know and what the future may hold. Curr Hematol Malig Rep, 2018, 13(3): 220-226. 36. Yoshida Y, Kato H, Ikeda Y, et al. Pathogenesis of atypical hemolytic uremic syndrome. J Atheroscler Thromb, 2019, 26(2): 99-110. 37. Rigothier C, Delmas Y, Roumenina LT, et al. Distal angiopathy and atypical hemolytic uremic syndrome: clinical and functional properties of an anti-factor H IgAλ antibody. Am J Kidney Dis, 2015, 66(2): 331-336.